Although contrast-enhanced ultrasound (CEUS) has become a widely utilized and accepted modality in much of the world, the associated contrast agents have only recently received approval in the United States. As with all radiological techniques, image…
With the recent FDA approval for characterization of focal liver lesions (FLL) in both pediatric and adult patients using Lumason (sulfur hexafluoride microbubbles), increased use of ultrasound contrast for routine clinical use is expected. This…
Contrast-enhanced ultrasound (CEUS) has become an established modality in various clinical indications for liver diseases. SonoVue((R)), a pure blood pure agent, and Sonazoid((R)), which exhibits an additional Kupffer phase, are contrast agents…
Purpose: To determine the indications for CEUS for renal mass evaluation.
Methods: This retrospective, single-center, IRB-approved, HIPAA compliant study analyzed data from 303 consecutive patients scheduled for a renal CEUS to determine the…
